Boditech Med Inc. (206640.KQ) has a MoatMap StockRank of 81/100 based on Quality (68/100), Value (59/100), and Momentum (37/100) factor scores. The current signal is STRONG BUY. Boditech Med is an in-vitro diagnostics company. Despite reasonable quality metrics, it lacks a strong global distribution moat and does not align with our 18-month macro themes.
Boditech Med Inc. is a South Korean in-vitro diagnostics company specializing in point-of-care testing (POCT) platforms and diagnostic reagents for cardiovascular, hormone, and infectious diseases. The company's competitive advantage is driven by its proprietary, high-precision reader instruments and a highly profitable razor-and-blade business model, where instrument installations drive recurring reagent sales. Boditech Med maintains a strong global footprint, exporting its diagnostic solutions to over 120 countries.
| Price | $6.76 |
| Market Cap | $156M |
| P/E (TTM) | 9.41 |
| Price/Book | 0.95 |
| Return on Equity | 10.8% |
| Return on Invested Capital | 10.9% |
| Debt/Equity | 5.38 |
| Gross Margin | 58.2% |
| Operating Margin | 15.9% |
| Revenue Growth | 9.6% |
| Dividend Yield | 1.4% |
| Free Cash Flow | $-11K |
Boditech Med Inc. operates in the Medical Devices industry, part of the Healthcare sector (South Korea).